Greenwich LifeSciences, Inc.
GLSI
$9.51
-$0.35-3.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -15.79M | -10.50M | -10.22M | -9.24M | -8.89M |
| Total Depreciation and Amortization | 3.60K | 3.60K | 3.60K | 3.60K | 3.60K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.25M | 2.38M | 2.38M | 2.38M | 2.38M |
| Change in Net Operating Assets | 1.27M | 545.10K | 1.05M | 154.00K | 31.50K |
| Cash from Operations | -7.27M | -7.57M | -6.79M | -6.70M | -6.48M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 4.37M | 4.25M | 3.07M | 299.10K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 4.37M | 4.25M | 3.07M | 299.10K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.90M | -3.32M | -3.72M | -6.41M | -6.48M |